MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab

MACROGENICS INC

FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.
Total potential regulatory milestones from Provention up to $170M; additional $225M in sales milestones.
Single-digit royalty on net sales of teplizumab payable to MacroGenics.
Cash runway extended into late 2024 based on existing cash and anticipated partner payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.